Avanafil API

Name	Avanafil
Chinese name	阿伐那非
Cas Number	330784-47-9
Source	India
Qualifications	USDMF/-/-/-/-

Developed by Japan's Tanabe Pharmaceutical Company and VIVUS, it was approved for listing in the United States on April 27, 2012. This product is a type 5 phosphodiesterase (PDE5) inhibitor, which can increase the blood flow of the penis. It is currently the first-line drug for the treatment of ED. The first-line drug for the treatment of ED includes sildenafil and vardenafil ), tadalafil (tadalafil) and avanafil (avanafil). As a second-generation PDE5 inhibitor, avanafil has the characteristics of fast onset and short duration, and increases the selectivity of PDE5 isoenzymes, which plays an important role in reducing the incidence of adverse reactions. Studies have shown that the drug can take effect in just 15 minutes, which is faster than 30-60 minutes reported by other drugs, and eating can affect the pharmacokinetics of sildenafil and vardenafil, but does not affect alva That's not. The rapid onset of avanafil allows ED patients to enjoy sex freely without having to take medication too early. It is a strong competitor of sildenafil (Viagra).

Hot Tags: avanafil api, China, suppliers, manufacturers, factory, customized, price, pricelist, in stock, Tippyridine Hydrochloride API, Lercanidipine Hydrochloride API, Temozolomide API, Dimethyl Fumarate API, Rasagiline Mesylate API, Pleasant API

• Previous: Lacosamide API
• Next: Lamotrigine API